CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| S1513 | SWOG | Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer | Adult CIRB - Late Phase Emphasis | Completed |
| S1608 | SWOG | Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1933 | SWOG | A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1011 | SWOG | A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
| S2000 | SWOG | A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1703 | SWOG | Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer | Cancer Prevention and Control CIRB | Available to Open |
| S0227 | SWOG | Phase III Randomized Trial of Cisplatin/Paclitaxel Versus Cisplatin/Gemcitabine in Recurrent; Persistent; or Metastatic Carcinoma of the Cervix | Adult CIRB - Late Phase Emphasis | Completed |
| S0106 | SWOG | A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg) during Induction Therapy Versus Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Gemtuzumab Ozogamicin (Mylotarg) or No Additional Therapy for Patients Under Age 61 with Previously Untreated De Novo Acute Myeloid Leukemia (AML) | Adult CIRB - Late Phase Emphasis | Completed |
| S1614 | SWOG | A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors | Cancer Prevention and Control CIRB | Available to Open |
| S2013 | SWOG | Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study | Cancer Prevention and Control CIRB | Available to Open |